|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||146.0 kg/mol g·mol−1|
|(what is this?)|
Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).
Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016. It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma.
- Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
- Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs: the investigational drugs journal. 13 (9): 601–604. PMID 20799138.
- AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- Nair, Parameswaran; Wenzel, Sally; Rabe, Klaus F.; Bourdin, Arnaud; Lugogo, Njira L.; Kuna, Piotr; Barker, Peter; Sproule, Stephanie; Ponnarambil, Sandhia; Goldman, Mitchell (2017). "Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma". New England Journal of Medicine. 376 (25): 2448. doi:10.1056/NEJMoa1703501. PMID 28530840.
- "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|